View Item 

Show simple item record

Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor‐induced colitis
dc.contributor.authorWright, Andrew P.
dc.contributor.authorPiper, Marc S.
dc.contributor.authorBishu, Shrinivas
dc.contributor.authorStidham, Ryan W.
dc.date.accessioned2019-06-20T17:05:41Z
dc.date.availableWITHHELD_13_MONTHS
dc.date.available2019-06-20T17:05:41Z
dc.date.issued2019-06
dc.identifier.citationWright, Andrew P.; Piper, Marc S.; Bishu, Shrinivas; Stidham, Ryan W. (2019). "Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor‐induced colitis." Alimentary Pharmacology & Therapeutics 49(12): 1474-1483.
dc.identifier.issn0269-2813
dc.identifier.issn1365-2036
dc.identifier.urihttps://hdl.handle.net/2027.42/149542
dc.publisherWiley Periodicals, Inc.
dc.titleSystematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor‐induced colitis
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelPharmacy and Pharmacology
dc.subject.hlbsecondlevelOtolaryngology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149542/1/apt15263_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/149542/2/apt15263.pdf
dc.identifier.doi10.1111/apt.15263
dc.identifier.sourceAlimentary Pharmacology & Therapeutics
dc.identifier.citedreferenceMartinez‐Balzano C. Management of ipilimumab‐induced colitis with concurrent clostridium difficile infection. Am J Gastroenterol. 2012; 107: S468.
dc.identifier.citedreferenceMitchell KA, Kluger H, Sznol M, Hartman DJ. Ipilimumab‐induced perforating colitis. J Clin Gastroenterol. 2013; 47: 781 ‐ 785.
dc.identifier.citedreferenceMurakami T, Pugh J, Ozden N, et al. Mimicking inflammatory bowel disease during treatment of metastatic melanoma: immune mediated ipilimumab‐induced colitis. Am J Gastroenterol. 2013; 108: S386 ‐ S387.
dc.identifier.citedreferenceO’Connor A, Marples M, Mulatero C, Hamlin J, Ford AC. Ipilimumab‐induced colitis: experience from a tertiary referral center. Therap Adv Gastroenterol. 2016; 9: 457 ‐ 462.
dc.identifier.citedreferencePagès C, Gornet JM, Monsel G, et al. Ipilimumab‐induced acute severe colitis treated by infliximab. Melanoma Res. 2013; 23: 227 ‐ 230.
dc.identifier.citedreferenceRyan D, Pasupuleti C, Butnariu M. Endoscopic remission after infliximab treatment in a patient with ipilimumab‐induced colitis. Am J Gastroenterol. 2016; 111: S812.
dc.identifier.citedreferenceSpain L, Walls G, Messiou C, Turajlic S, Gore M, Larkin J. Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series. Cancer Immunol Immunother. 2017; 66: 113 ‐ 117.
dc.identifier.citedreferenceTsiaras A. Case of the month. Autoimmune colitis secondary to CTLA‐4 blockade. JAAPA. 2011; 24: 68.
dc.identifier.citedreferenceYarze J, Stoutenburg J. Ipilimumab‐associated colitis. Am J Gastroenterol. 108 ( Suppl. 1 ): S357.
dc.identifier.citedreferenceSpain L, Diem S, Khabra K, et al. Patterns of steroid use in diarrhoea and/or colitis (D/C) from immune checkpoint inhibitors (ICPI). Ann Oncol. 2016; 27 (Suppl. 6 ): vi359 – vi378.
dc.identifier.citedreferenceBeck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T‐lymphocyte‐associated antigen 4. J Clin Oncol. 2006; 24: 2283 ‐ 2289.
dc.identifier.citedreferenceMessmer M, Upreti S, Tarabishy Y, et al. Ipilimumab‐induced enteritis without colitis: a new challenge. Case Rep Oncol. 2016; 9: 705 ‐ 713.
dc.identifier.citedreferenceBoike J, Dejulio T. Severe esophagitis and gastritis from nivolumab therapy. ACG Case Rep J. 2017; 4: e57.
dc.identifier.citedreferenceGatto NM, Frucht H, Sundararajan V, Jacobson JS, Grann VR, Neugut AI. Risk of perforation after colonoscopy and sigmoidoscopy: a population‐based study. J Natl Cancer Inst. 2003; 95: 230 ‐ 236.
dc.identifier.citedreferenceLüning TH, Keemers‐Gels ME, Barendregt WB, Tan A, Rosman C. Colonoscopic perforations: a review of 30,366 patients. Surg Endosc. 2007; 21: 994 ‐ 997.
dc.identifier.citedreferenceNavaneethan U, Kochhar G, Phull H, et al. Severe disease on endoscopy and steroid use increase the risk for bowel perforation during colonoscopy in inflammatory bowel disease patients. J Crohns Colitis. 2012; 6: 470 ‐ 475.
dc.identifier.citedreferenceGarcia‐Neuer M, Marmarelis ME, Jangi SR, et al. Diagnostic comparison of CT scans and colonoscopy for immune‐related colitis in ipilimumab‐treated advanced melanoma patients. Cancer Immunol Res. 2017; 5: 286 ‐ 291.
dc.identifier.citedreferenceAbu‐Sbieh H, Ali FS, Luo W, et al. Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor‐induced colitis. J Immunother Cancer. 2018; 6: 1474 ‐ 11.
dc.identifier.citedreferenceGeukes Foppen MH, Rozeman EA, van Wilpe S, et al. Immune checkpoint inhibition‐related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018; 3: 1474 ‐ 8.
dc.identifier.citedreferencePostow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015; 33: 1974 ‐ 1982.
dc.identifier.citedreferenceGupta A, De Felice KM, Loftus EV, Khanna S. Systematic review: colitis associated with anti‐CTLA‐4 therapy. Aliment Pharmacol Ther. 2015; 42: 406 ‐ 417.
dc.identifier.citedreferenceEggermont A, Chiarion‐Sileni V, Grob J‐J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med. 2016; 375: 1845 ‐ 1855.
dc.identifier.citedreferenceLarkin J, Chiarion‐Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373: 23 ‐ 34.
dc.identifier.citedreferenceBrahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune‐related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36: 1714 ‐ 1768.
dc.identifier.citedreferenceVerschuren EC, van den Eertwegh AJ, Wonders J, et al. Clinical, endoscopic, and histologic characteristics of ipilimumab‐associated colitis. Clin Gastroenterol Hepatol. 2016; 14: 836 ‐ 842.
dc.identifier.citedreferenceMarthey L, Mateus C, Mussini C, et al. Cancer immunotherapy with anti‐CTLA‐4 monoclonal antibodies induces an inflammatory bowel disease. J Crohns Colitis. 2016; 10: 395 ‐ 401.
dc.identifier.citedreferenceHillock NT, Heard S, Kichenadasse G, et al. Infliximab for ipilimumab‐induced colitis: A series of 13 patients. Asia Pac J Clin Oncol. 2017; 13: e284 - e290.
dc.identifier.citedreferenceYanai S, Nakamura S, Matsumoto T. Nivolumab‐induced colitis treated by infliximab. Clin Gastroenterol Hepatol. 2017; 15: e80 - 81.
dc.identifier.citedreferenceGondal B, Patel P, Gallan A, et al. Gastrointestinal adverse effects of immunomodulation: acute colitis with immune check point inhibitor nivolumab. Inflammatory Bowel Dis. 2016; 22: S12 ‐ S13.
dc.identifier.citedreferenceBaroudjian B, Lourenco N, Pagès C, et al. Anti‐PD1‐induced collagenous colitis in a melanoma patient. Melanoma Res. 2016; 26: 308 ‐ 311.
dc.identifier.citedreferenceHanauer DA, Mei Q, Law J, Khanna R, Zheng K. Supporting information retrieval from electronic health records: a report of University of Michigan’s nine‐year experience in developing and using the Electronic Medical Record Search Engine (EMERSE). J Biomed Inform. 2015; 55: 290 ‐ 300.
dc.identifier.citedreferenceLord JD, Hackman RC, Moklebust A, et al. Refractory colitis following anti‐CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci. 2010; 55: 1396 ‐ 1405.
dc.identifier.citedreferenceSidhu M, Mersaides T, Liniker E, et al. Infliximab for the treatment of Ipilimumab (anti CTLA‐4) and Nivolumab/Pembrolizumab (anti PD‐1) associated colitis. J Gastroenterol Hepatol. 2015; 30: 139.
dc.identifier.citedreferenceAgarwal A, Maru D. Histologpic spectrum of ipilimumab associated colitis is narrow and resembles inflammatory bowel disease. Lab Invest. 2016; 96: 158A – 159A.
dc.identifier.citedreferenceBakeri H, Olson E, Ihunnah C, et al. A melancholy colitis with a curious REMI‐DY. Am J Gastroenterol. 2016; 111: S662 ‐ S663.
dc.identifier.citedreferenceBamias G, Delladetsima I, Perdiki M, et al. Immunological characteristics of colitis associated with anti‐CTLA‐4 antibody therapy. Cancer Invest. 2017; 3: 1474 ‐ 13.
dc.identifier.citedreferenceBalaphas A, ResteIlini S, Robert‐Yap J, Morel P, Roche B, Ris F. A case of ipilimumab‐induced anorectal fistula. J Crohns Colitis. 2016; 10: 501 ‐ 502.
dc.identifier.citedreferenceBarina AR, Bashir MR, Howard BA, Hanks BA, Salama AK, Jaffe TA. Isolated recto‐sigmoid colitis: a new imaging pattern of ipilimumab‐associated colitis. Abdom Radiol. 2016; 41: 207 ‐ 214.
dc.identifier.citedreferenceBeniwal‐Patel P, Matkowskyj K, Caldera F. Infliximab therapy for corticosteroid‐resistant ipilimumab‐induced colitis. J Gastrointestin Liver Dis. 2015; 24: 274.
dc.identifier.citedreferenceCheng R, Cooper A, Kench J, et al. Ipilimumab‐induced toxicities and the gastroenterologist. J Gastroenterol Hepatol. 2015; 30: 657 ‐ 666.
dc.identifier.citedreferenceDe Felice K, Raffals L. High dose budesonide in steroid refractory ipilimumab‐induced colitis. Inflammatory Bowel Dis. 2013; 19: S26.
dc.identifier.citedreferenceGao J, He Q, Subudhi S, et al. Review of immune‐related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene. 2015; 34: 5411 ‐ 5417.
dc.identifier.citedreferenceGao Y, Sharma S, Boparai R. Dire diarrhea: Ipilimumab induced colitis and its management. J Gen Intern Med. 2014; 29: S345.
dc.identifier.citedreferenceGarcía‐Varona A, Odze RD, Makrauer F. Lymphocytic colitis secondary to ipilimumab treatment. Inflamm Bowel Dis. 2013; 19: E15 ‐ E16.
dc.identifier.citedreferenceGupta A, Khanna S. Ipilimumab‐associated colitis or refractory Clostridium difficile infection? BMJ Case Rep. 2015. https://doi.org/10.1136/bcr-2015-211160:1-3
dc.identifier.citedreferenceHinds A, Ahmad D, Muenster J, et al. Ipilimumab‐induced colitis: a rare but serious side effect. Am J Gastroenterol. 2013; 108: S374 ‐ S375.
dc.identifier.citedreferenceJain A, Lipson EJ, Sharfman W, et al. Clinical features and treatment of immune mediated colitis in metastatic melanoma patients treated with ipilimumab: retrospective review of a single‐center experience. Gastroenterology. 2014; 146: S–352.
dc.identifier.citedreferenceKlair JS, Girotra M, Hutchins LF, Caradine KD, Aduli F, Garcia‐Saenz‐de‐Sicilia M. Ipilimumab‐induced gastrointestinal toxicities: a management algorithm. Dig Dis Sci. 2016; 61: 2132 ‐ 2139.
dc.identifier.citedreferenceKoch C, Paetzold S, Trojan J. Enterocolitis in a patient being treated with ipilimumab for metastatic melanoma. Gastroenterology. 2012; 143: 298, 504–505.
dc.identifier.citedreferenceLankes K, Hundorfean G, Harrer T, et al. Anti‐TNF‐refractory colitis after checkpoint inhibitor therapy: possible role of CMV‐mediated immunopathogenesis. Oncoimmunology. 2016; 5: e1128611.
dc.identifier.citedreferenceMaker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte‐associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol. 2005; 12: 1005 ‐ 1016.
dc.identifier.citedreferenceMcCutcheon, JL. Infectious colitis associated with ipilimumab therapy. Gastroenterol Res. 2014; 7: 28 ‐ 31.
dc.identifier.citedreferenceMinor DR, Puzanov I, Callahan MK, Hug BA, Hoos A. Severe gastrointestinal toxicity with administration of trametinib in combination with dabrafenib and ipilimumab. Pigment Cell Melanoma Res. 2015; 28: 611 ‐ 612.
dc.identifier.citedreferenceMuhammad A, Reed J, Vidyarthi G, et al. Drug induced colon injury (DICI): a case of ipilimumab induced immune related colitis. Am J Gastroenterol. 2012; 107: S456.
dc.identifier.citedreferenceNancey S, Boschetti G, Cotte E, et al. Blockade of cytotoxic T‐lymphocyte antigen‐4 by ipilimumab is associated with a profound long‐lasting depletion of Foxp3+ regulatory T cells: a mechanistic explanation for ipilimumab‐induced severe enterocolitis? Inflamm Bowel Dis. 2012; 18: E1598 ‐ E1600.
dc.identifier.citedreferencePenumetsa K, Ponugoti S, Reynolds G. Ipilimumab‐induced colitis with concomitant clostridium difficile infection. Am J Gastroenterol. 2013; 108: S392.
dc.identifier.citedreferencePocha C, Roat J, Viskocil K. Immune‐mediated colitis: important to recognize and treat. J Crohns Colitis. 2014; 8: 181 ‐ 182.
dc.identifier.citedreferenceRastogi P, Sultan M, Charabaty AJ, et al. Ipilimumab associated colitis: an IpiColitis case series at MedStar Georgetown University Hospital. World J Gastroenterol. 2015; 21: 4373 ‐ 4378.
dc.identifier.citedreferenceRini BI, Stein M, Shannon P, et al. Phase 1 dose‐escalation trial of tremelimumab plus sunitinib in patients with metastatic renal cell carcinoma. Cancer. 2010; 117: 758 ‐ 767.
dc.identifier.citedreferenceRomain P, Salama A, Lynn Ferguson N, et al. Ipilimumab‐associated lymphocytic colitis: a case report. Transl Gastroenterol Hepatol. 2016; 5: 44 ‐ 46.
dc.identifier.citedreferenceSampath AM. A rare presentation of severe colitis with ipilimumab therapy. Am J Gastroenterol. 2013; 108: S399.
dc.identifier.citedreferenceSanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti‐cytotoxic T‐lymphocyte antigen‐4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. JCO. 2005; 23: 741 ‐ 750.
dc.identifier.citedreferenceSlangen R, Eertwegh A, Bodegraven A, Boer NKHd. Diarrhoea in a patient with metastatic melanoma: Ipilimumab ileocolitis treated with infliximab. World J Gastrointest Pharmacol Ther. 2013; 4: 80 ‐ 82.
dc.identifier.citedreferenceSatoh T, Ohno K, Kurokami T. Endoscopic findings of ipilimumab‐induced colitis. Dig Endosc. 2017; 29: 388 - 389.
dc.identifier.citedreferenceSprung B, Sathyamurthy A, Lewis J, et al. A case of perforating ipilimumab‐induced autoimmune colitis. Am J Gastroenterol. 2014; 109: S409.
dc.identifier.citedreferenceSreepati G, Kalra M, Aggarwal A. Abdominal imaging is insensitive in diagnosis of ipilimumab‐induced colitis. Am J Gastroenterol. 2014; 109: S428.
dc.identifier.citedreferenceTondon R, Shroff SG, Furth EE, et al. Ipilimumab induced perforating colitis: severe cases mimic crohn disease and ulcerative colitis. Lab Invest. 2016; 96: 203A.
dc.identifier.citedreferenceUslu U, Agaimy A, Hundorfean G, Harrer T, Schuler G, Heinzerling L. Autoimmune colitis and subsequent CMV‐induced hepatitis after treatment with ipilimumab. J Immunother. 2015; 38: 212 ‐ 215.
dc.identifier.citedreferenceVenditti O, De Lisi D, Caricato M, et al. Ipilimumab and immune‐mediated adverse events: a case report of anti‐CTLA4 induced ileitis. BMC Cancer. 2015; 15: 87.
dc.identifier.citedreferenceAmer S, Horsley‐Silva JL, Noelting J, et al. Ipilimumab‐induced colitis. Am J Gastroenterol. 2015; 110: S282.
dc.identifier.citedreferenceDe Felice KM, Gupta A, Rakshit S, et al. Ipilimumab‐induced colitis in patients with metastatic melanoma. Melanoma Res. 2015; 25: 321 ‐ 327.
dc.identifier.citedreferenceHaider A, O’Riordan K. Ipilimumab‐induced colonic perforation. Am J Gastroenterol. 2014; 109: S421 ‐ S422.
dc.identifier.citedreferenceKoya HH, Varghese D, John S. A case of severe enterocolitis secondary to a novel biological agent. Am J Gastroenterol. 2013; 108: S406 ‐ S407.
dc.identifier.citedreferenceHodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte‐associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA. 2008; 105: 3005 ‐ 3010.
dc.identifier.citedreferenceHsieh A, Ferman M, Brown MP, et al. A novel treatment for ipilimumab‐induced colitis. BMJ Case Rep. 2016: 1474 - 4. https://doi.org/10.1136/bcr-2016-216641
dc.identifier.citedreferenceJohnston RL, Lutzky J, Chodhry A, Barkin JS. Cytotoxic T‐lymphocyte‐associated antigen 4 antibody‐induced colitis and its management with infliximab. Dig Dis Sci. 2009; 54: 2538 ‐ 2540.
dc.identifier.citedreferenceKhanijow V, Chablaney S, Bashir S, et al. Ipilimumab enterocolitis: An unusual case of colonic perforation and death. Am J Gastroenterol. 2015; 110: S147.
dc.identifier.citedreferenceLeggett C, Hart P, Mounajjed T, et al. I pilimumab Induced Enterocolitis ‐ A Novel Cause of Diarrhea. Am J Gastroenterol. 2011; 106: S319.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
apt15263_am.pdf
Size:
354.5KB
Format:
PDF
View/Open
Name:
apt15263.pdf
Size:
569.4KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.